RemeGen Co., Ltd. (9995.HK) Bundle
Who is buying RemeGen (9995.HK) - and why does it matter? Dive into a shareholder map where the largest single holder, Yantai Rongda Venture Capital Center (Limited Partnership), controls 18.42% of the company (about 102,381,891 shares) valued at roughly HK$7.85 billion, institutional vehicles like mutual funds and ETFs own 24.36% (135.41 million shares), other institutions account for a commanding 48.13% and retail/public companies hold 27.52% - all against a backdrop in which market capitalization has surged to HK$47.01 billion (a 192.32% rise year-over-year) while the company reported CNY 1,719.83 million in revenue for the nine months to Sept 30, 2025 and a narrowed net loss of CNY 550.7 million; investors cite a deepening pipeline - notably Telitacicept (RC18) for autoimmune disease and Disitamab Vedotin (RC48) for oncology - as the strategic rationale behind this concentrated institutional interest.
RemeGen Co., Ltd. (9995.HK) - Who Invests in RemeGen Co., Ltd. and Why?
RemeGen attracts a mix of strategic large shareholders, institutional investors, and retail participants drawn by a deep clinical pipeline, commercial progress, and expanding market valuation.- Major strategic holder: Yantai Rongda Venture Capital Center (Limited Partnership) - 18.42% (102,381,891 shares; ~HK$7.85 billion) as of April 2, 2025.
- Institutional investors (mutual funds, ETFs): 24.36% - 135.41 million shares; ~HK$10.39 billion.
- Other institutional investors: 48.13% - 267.55 million shares; ~HK$20.52 billion.
- Retail investors & public companies: 27.52% - 152.98 million shares; ~HK$11.73 billion.
| Holder Type | Percentage | Shares (million) | Approx. Value (HK$ billion) | Reference Date |
|---|---|---|---|---|
| Yantai Rongda Venture Capital Center (LP) | 18.42% | 102.382 | 7.85 | April 2, 2025 |
| Institutional (mutual funds & ETFs) | 24.36% | 135.410 | 10.39 | April 2, 2025 |
| Other institutional investors | 48.13% | 267.550 | 20.52 | April 2, 2025 |
| Retail investors & public companies | 27.52% | 152.980 | 11.73 | April 2, 2025 |
| Total market capitalization (one-year change) | HK$47.01 billion (▲192.32% over past year) | Dec 15, 2025 | ||
- Pipeline strength: Telitacicept (RC18) targeting autoimmune disorders - attracts investors seeking large chronic-market opportunities.
- Oncology franchise: Disitamab Vedotin (RC48) - marketed and partnered potential in solid tumors drives commercial upside expectations.
- Valuation momentum: Market cap up 192.32% year-over-year to HK$47.01 billion (Dec 15, 2025), signaling rising investor confidence and liquidity.
- Institutional confidence: Combined institutional ownership (24.36% + 48.13%) reflects active fund allocation to China biopharma exposure.
- Strategic anchor: Yantai Rongda's 18.42% stake provides perceived stability and alignment with long-term development.
- Long-term holders (venture/strategic): Focus on pipeline milestones, regulatory approvals, and partnership/licensing deals.
- Mutual funds & ETFs: Provide liquidity and can amplify moves on positive clinical/commercial news; concentrated ownership increases sensitivity to flows.
- Retail/public companies: Add volatility around news events but contribute to broader market visibility.
RemeGen Co., Ltd. (9995.HK) Institutional Ownership and Major Shareholders of RemeGen Co., Ltd. (9995.HK)
RemeGen Co., Ltd. (9995.HK) exhibits a strong institutional shareholder base, with a mix of strategic venture capital, mutual funds/ETFs, other institutional investors, and retail/public company holdings. Recent figures through April 2, 2025 and financials through September 30, 2025, plus market-cap data to December 15, 2025, underscore why institutions are allocating to the name.
- Largest shareholder: Yantai Rongda Venture Capital Center (Limited Partnership) - 18.42% (as of April 2, 2025).
- Mutual funds and ETFs (collective): 24.36% - signaling concentrated fund-level exposure.
- Other institutional investors: 48.13% - a dominant institutional presence across pensions, asset managers, and strategic holders.
- Retail investors and public companies: 27.52% - a meaningful free-float component supporting liquidity.
| Metric | Value | As of / Period |
|---|---|---|
| Largest shareholder | Yantai Rongda Venture Capital Center (Limited Partnership) - 18.42% | April 2, 2025 |
| Mutual funds & ETFs | 24.36% | April 2, 2025 |
| Other institutional investors | 48.13% | April 2, 2025 |
| Retail investors & public companies | 27.52% | April 2, 2025 |
| Market capitalization | HK$47.01 billion | December 15, 2025 (YoY +192.32%) |
| Revenue (9 months) | CNY 1,719.83 million | Period ended Sep 30, 2025 |
| Net loss (9 months) | CNY 550.7 million (reduced) | Period ended Sep 30, 2025 |
Drivers behind institutional interest include improving top-line momentum and narrowing losses, which large holders often interpret as de-risking ahead of commercialization milestones or regulatory progress. The composition - nearly three-quarters institutional when combining mutual funds/ETFs and other institutions - suggests both active and passive allocations.
- Fund/ETF ownership (24.36%): provides stable trading volume and potential for index-related inflows.
- Strategic venture capital (18.42% by Yantai Rongda): indicates aligned long-term support and potential board/influence access.
- Other institutions (48.13%): diversified institutional conviction reducing single-point concentration risk despite the large VC stake.
For deeper financial detail and analysis tied to these ownership trends, see: Breaking Down RemeGen Co., Ltd. Financial Health: Key Insights for Investors
RemeGen Co., Ltd. (9995.HK) - Key Investors and Their Impact on RemeGen Co., Ltd.
RemeGen's shareholder base as of April 2, 2025 and market performance through December 15, 2025 show concentrated strategic backing from private investors and strong institutional participation. Major holders and the allocation of capital across investor types help explain the stock's significant re-rating and the sources of ongoing financing and market support.- Yantai Rongda Venture Capital Center (Limited Partnership) - anchor strategic investor holding 18.42% (102,381,891 shares), valued at ~HK$7.85 billion.
- Mutual funds and ETFs - collective institutional demand at 24.36% (135.41 million shares), valued at ~HK$10.39 billion.
- Other institutional investors - broad institutional ownership at 48.13% (267.55 million shares), valued at ~HK$20.52 billion.
- Retail investors and public companies - significant public float at 27.52% (152.98 million shares), valued at ~HK$11.73 billion.
| Investor Category | % Ownership | Shares (approx.) | Value (HK$) |
|---|---|---|---|
| Yantai Rongda Venture Capital Center (LP) | 18.42% | 102,381,891 | 7,850,000,000 |
| Mutual funds & ETFs | 24.36% | 135,410,000 | 10,390,000,000 |
| Other institutional investors | 48.13% | 267,550,000 | 20,520,000,000 |
| Retail investors & public companies | 27.52% | 152,980,000 | 11,730,000,000 |
| Total market capitalization (12/15/2025) | HK$47,010,000,000 (↑192.32% YoY) | ||
- Pipeline upside: Telitacicept (RC18) for autoimmune indications and Disitamab Vedotin (RC48) for oncology represent core commercialization and licensing value drivers.
- Commercial traction and partner deals: Institutional buyers favor companies with demonstrated out-licensing or co-development opportunities that can monetize late-stage assets.
- Balance of strategic vs. passive ownership: Large strategic LP stakes (e.g., Yantai Rongda) signal long-term alignment, while mutual funds/ETFs provide liquidity and valuation support.
- Volatility and retail participation: Retail/public-company holders increase float and trading volume, contributing to repricing during positive clinical or regulatory events.
- High institutional ownership (combined >72% when counting mutual funds/ETFs and other institutions) supports tighter spreads and potentially more stable share-price reactions to clinical data and licensing news.
- Large anchor stake by Yantai Rongda reduces free float concentration risk while aligning private capital with corporate strategy and long-term value capture.
- Market cap expansion of 192.32% to HK$47.01 billion (as of 15‑Dec‑2025) reflects growing investor confidence tied to RC18 and RC48 development, and likely improved revenue/projection visibility.
RemeGen Co., Ltd. (9995.HK) - Market Impact and Investor Sentiment
RemeGen's market valuation and recent operating results have materially altered investor perceptions, driven by clinical progress and improving top-line momentum. The company's market capitalization surged 192.32% over the past year to HK$47.01 billion as of December 15, 2025, signaling notable investor appetite despite ongoing losses. For the nine months ended September 30, 2025, revenue reached CNY 1,719.83 million and net loss narrowed to CNY 550.7 million, reflecting progress toward profitability.- Market cap (12/15/2025): HK$47.01 billion (↑192.32% YoY)
- Revenue (9M ended 30 Sep 2025): CNY 1,719.83 million
- Net loss (9M ended 30 Sep 2025): CNY 550.7 million (reduced vs prior periods)
- Ticker: 9995.HK
| Metric | Value | Period / Date |
|---|---|---|
| Market Capitalization | HK$47.01 billion | 15-Dec-2025 |
| 1-Year Market Cap Change | +192.32% | Year to 15-Dec-2025 |
| Revenue | CNY 1,719.83 million | 9M to 30-Sep-2025 |
| Net Loss | CNY 550.7 million | 9M to 30-Sep-2025 |
| Key Pipeline Assets | Telitacicept (RC18); Disitamab Vedotin (RC48) | Clinical / Commercial stages |
| Analyst Sentiment | Mixed - Neutral to Sell | Various broker reports |
- Attraction points for investors:
- Strong market cap recovery and share price momentum
- Commercial progress of Disitamab Vedotin (RC48) in oncology
- Broader pipeline including Telitacicept (RC18) targeting autoimmune diseases
- Revenue growth and narrowing net losses indicating operational improvement
- Risk/hesitation factors:
- Mixed analyst ratings (Neutral to Sell) reflecting uncertainty on execution
- Need for continued commercial traction and margin expansion
- Regulatory and competitive risks inherent in biotech
RemeGen Co., Ltd. (9995.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.